News

TASTE: Thrombus aspiration has no mortality benefit in STEMI


 

FROM THE ESC CONGRESS 2013

"Today it may be possible to design and conduct megatrials with what we have: bigger data and smaller budgets," they wrote. "Yet we must also recognize and acknowledge the daunting challenges that diverse groups of researchers and stakeholders must overcome to get there."

TASTE was funded by the Swedish Research Council and Swedish Association of Local Authorities and Regions. Dr. Fröbert also reported unrestricted grants from Terumo, Medtronic, and Vascular Solutions, and consultancy for Stentys and Biotronik. His coauthors reported financial ties with numerous research and commercial entities. Dr. Lauer, Dr. D’Agostino, and Dr. Byrne reported having no relevant financial conflicts. Dr. Kastrati reported receiving fees from Biotronik, the Medicines, Astra-Zeneca, MSD, St. Jude Medical, and Biosensors.

pwendling@frontlinemedcom.com

Pages

Recommended Reading

Azithromycin cardiovascular risk perhaps in subgroup only
MDedge Family Medicine
Acute MI patients benefit from early rehabilitation
MDedge Family Medicine
Telemonitored cardiac rehabilitation boosts compliance
MDedge Family Medicine
Treadmill 1-km walk test predicts prognosis in cardiac disease
MDedge Family Medicine
FDA panel starts review of rosiglitazone CV data
MDedge Family Medicine
Physician passengers handle half of in-flight emergencies
MDedge Family Medicine
Cholinesterase inhibitors may protect the heart
MDedge Family Medicine
FDA panels revisit rosiglitazone's cardiovascular safety
MDedge Family Medicine
ACS stent thrombosis indication for rivaroxaban not approved, company says
MDedge Family Medicine
Will a novel antibody fix the anticoagulant-bleeding problem?
MDedge Family Medicine